- GlaxoSmithKline PLC stock price today and history
GlaxoSmithKline PLC (GSK) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
GlaxoSmithKline PLC stock price
GlaxoSmithKline PLC latest news:
BRIEF-ACCC Institutes Proceedings Against GSK, Novartis
Australian Competition and Consumer Commission. * INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD AND NOVARTIS CONSUMER HEALTH AUSTRALASIA. * PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.
GSK starts big African study of injectable drug to prevent HIV
ViiV Healthcare, GlaxoSmithKline Plc's HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women. The cabotegravir study seeks to enrol 3,200 women aged 18 to 45 years from sub-Saharan African countries, ViiV Healthcare said in a statement.
BRIEF-Glaxosmithkline says ViiV Healthcare starts Phase 3 HIV prevention study in women
* VIIV HEALTHCARE, CO OWNED BY GSK, WITH PFIZER INC. AND
LTD AS SHAREHOLDERS, TO START PHASE III STUDY FOR PREVENTION OF
HIV INFECTION IN SEXUALLY ACTIVE WOMEN
Source text for Eikon:
Further company coverage:
ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. The therapy, Juluca, is the first such HIV drug composed of just two drugs -- dolutegravir and rilpivirine, both of which have been previously approved -- while other HIV regimens are typically composed of at least three drugs. This advancement could make the regimen more tolerable for the patient, according to Dr. Debra Birnkrant, director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research. Juluca is approved for individuals with HIV-1 who have been stable on a regimen for at least half a year, have no history of treatment failure and no known resistance to Juluca's individual components, ViiV said. GlaxoSmithKline shares declined 0.8% in Tuesday trade; shares have dropped nearly 10% over the last three months, compared with a 7% rise in the S&P 500 and a nearly 8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-GlaxoSmithKline reports 13.3 percent stake in Spero Therapeutics
Spero Therapeutics Inc(SPRO). * GlaxoSmithKline PLC reports a 13.3 percent stake in Spero Therapeutics Inc (SPRO) as of November 6 - SEC filing Source text: Further company coverage:
BRIEF-Glaxosmithkline says results of first study assessing levels of organ damage in patients with active SLE
GLAXOSMITHKLINE PLC(GSK): * SAYS RESULTS OF FIRST STUDY ASSESSING LEVELS OF ORGAN DAMAGE IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH BENLYSTA PLUS STANDARD OF CARE VERSUS SOC ALONE. * PATIENTS WITH SLE ARE AT RISK OF IRREVERSIBLE ORGAN DAMAGE, WHICH CAN ACCRUE OVER TIME AND IS ASSOCIATED WITH INCREASED RISK OF DEATH. * SAFETY PROFILE OBSERVED IN BLISS-76 LONG-TER...
Pfizer sets date for auction of consumer healthcare unit: Reuters
Pfizer Inc. will begin the auction process for its consumer healthcare unit in November, which it hopes will end in a $15 billion sale, Reuters reported late Wednesday, citing sources close to the matter. GlaxoSmithKline PLC. and Reckitt Benckiser are among those companies that have said they would consider bidding for the Pfizer unit. One of the sources told Reuters that initial discussions with Reckitt have already happened. Other possible bidders may include Procter & Gamble , Sanofi SA , Johnson & Johnson and Nestle [s:
ch:nesn], sources said. The companies have been contacted for comment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
GlaxoSmithKline stock plummets 6% after concerns about dividend risk
GlaxoSmithKline PLC shares plummeted 6% in extremely heavy midday trade Wednesday on concerns that the company's interest in Pfizer Inc.'s over-the-counter business could put its dividend at risk. After being asked if she could give investors assurances that the potential deal would carry no dividend risk, Chief Executive Emma Walmsley did not exactly give those assurances. "We know the dividend matters to our investors. We intend and we do pay it now as a function of our free cash flow after investing in the necessary priorities to secure long-term growth for the company," Walmsley said, according to the FactSet transcript of the company's third-quarter earnings call, adding, "we confirmed our intentions to pay the dividend in 2017 of 80 pence and again in 2018 and then we will be returning to declaring the dividend quarterly and not giving a more specific outlook beyond that." When Walmsley was again pressed about the potential Pfizer deal, she said it was "too premature and hypothetical." "For us, even though we believe pricing (mostly in Respiratory) and competitive concerns (Respiratory and HIV) are largely factored into the stock at current levels, investors remain focused on the safety of the dividend," said Leerink Partners analyst Seamus Fernandez. GlaxoSmithKline shares have dropped 9.5% over the last three months, compared with a 2.9% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
GlaxoSmithKline on target thanks to HIV and lung drugs
Pharmaceutical giant GlaxoSmithKline's third-quarter sales are helped by demand for new products.
GlaxoSmithKline adult shingles vaccine wins U.S. approval
The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday.
BRIEF-Glaxosmithkline says shingles vaccine approved in Canada
Glaxosmithkline Plc(GSK): * SHINGRIX HAS BEEN APPROVED IN CANADA FOR PREVENTION OF SHINGLES IN PEOPLE AGED 50 YEARS OR OLDER. * APPROVAL IN CANADA WAS BASED ON PHASE III CLINICAL TRIAL PROGRAMME EVALUATING ITS EFFICACY, SAFETY AND IMMUNOGENICITY IN MORE THAN 37,000 PEOPLE Source text for Eikon: Further company coverage:
BRIEF-GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD
* CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY
SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED
BRIEF-GlaxoSmithKline says Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from CHMP in Europe
* TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY
RECEIVES POSITIVE OPINION FROM THE CHMP IN EUROPE FOR
APPROPRIATE PATIENTS WITH COPD
Global Brass and Copper HoldingsBRSS
Global Cash Access HoldingsGCA
Global High Income Dollar FundGHI
Global Net LeaseGNL
Global Partners LPGLP
Global Payments Inc.GPN
Global Power Equipment Group IncGLPW
Global Ship LeaseGSL
Global Ship LeaseGSL^B